Related Experiment Video
Updated: Jan 22, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Epidermal Growth Factor Receptor-Targeted Delivery of a Singlet-Oxygen Sensitizer with Thermal Controlled Release for
Juanjuan Chen1, Dongyao Li1, Beibei Huo1
1National and Local Joint Biomedical Engineering Research Center on Photodynamic Technologies, College of Chemistry , Fuzhou University , Fuzhou 350116 , Fujian , China.
Abstract:
Photodynamic therapy (PDT) utilizing light-induced singlet oxygen has achieved attractive results in anticancer fields; however, its development is hindered by limited light penetration depth, skin phototoxicity, tumor hypoxia, and PDT-induced hypoxia. Inspired by our previous research work and the limitations of PDT, we introduce a small-molecule-targeted drug erlotinib into the singlet-oxygen chemical source endoperoxide to achieve an EGFR-targeted PDT-mimetic sensitizer (Y3-1) for anticancer therapy. We demonstrated the erlotinib-based precise delivery of the singlet-oxygen chemical source (in vitro photosensitization) to EFGR-overexpressing tumor cells and tissues. Moreover, the anticancer assays validated that the enhanced anticancer efficacy (in vitro and in vivo) of Y3-1 was due to reversible singlet-oxygen thermal release. This study is expected to provide a smart strategy to break through the current roadblock in targeted PDT and achieve a more efficient anticancer therapy model.
Insights
A novel EGFR-targeted sensitizer, Y3-1, overcomes photodynamic therapy limitations by precisely delivering singlet oxygen to tumors. This approach enhances anticancer efficacy both in vitro and in vivo.
Area of Science:
- Biomedical Engineering
- Chemical Biology
- Oncology
Background:
- Photodynamic therapy (PDT) shows promise in cancer treatment but faces challenges like limited light penetration and hypoxia.
- Existing PDT methods struggle with targeted delivery and can cause phototoxicity and tumor hypoxia.
Purpose of the Study:
- To develop an Epidermal Growth Factor Receptor (EGFR)-targeted photosensitizer (Y3-1) that mimics PDT effects.
- To overcome PDT limitations by using erlotinib for precise delivery of a singlet oxygen source.
Main Methods:
- Synthesized a novel small-molecule sensitizer (Y3-1) by incorporating erlotinib into a singlet oxygen chemical source.
- Evaluated Y3-1 for targeted delivery and photosensitization in EGFR-overexpressing cancer cells and tissues in vitro.
- Assessed the in vitro and in vivo anticancer efficacy of Y3-1, investigating the mechanism of singlet oxygen thermal release.
Main Results:
- Demonstrated precise delivery of the singlet oxygen source to EGFR-overexpressing tumor cells and tissues via erlotinib targeting.
- Validated enhanced anticancer efficacy of Y3-1 through reversible singlet oxygen thermal release.
- Showcased significant in vitro and in vivo anticancer activity of the novel sensitizer.
Conclusions:
- Y3-1 acts as an effective EGFR-targeted PDT-mimetic sensitizer for anticancer therapy.
- The study presents a novel strategy to address current limitations in targeted PDT.
- This approach offers a pathway toward more efficient and targeted cancer treatment models.
More Related Videos
09:16Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy
Published on: September 11, 2015
08:39Magnetic and Thermal-sensitive PolyN-isopropylacrylamide-based Microgels for Magnetically Triggered Controlled Release
Published on: July 4, 2017
Related Concept Videos
Oxygen Requirements and Growth Patterns
Targeted Cancer Therapies
There are several types of targeted therapies against...
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Factors Influencing Microbial Growth: pH
Methods for Controlling Microbial Growth
Factors Influencing Microbial Growth: Temperature